+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leukemia Therapeutics - Global Strategic Business Report 2026

  • PDF Icon

    Report

  • 581 Pages
  • November 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5309480
The global market for Leukemia Therapeutics was valued at US$21.4 Billion in 2025 and is projected to reach US$32.1 Billion by 2032, growing at a CAGR of 5.9% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Leukemia Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Demand for Leukemia Therapeutics Growing Rapidly?

The leukemia therapeutics market is experiencing rapid growth as the incidence of leukemia continues to rise globally. Leukemia, a type of cancer affecting the blood and bone marrow, has seen an increase in cases due to factors such as aging populations and environmental influences. The growing demand for effective treatments is driving the development of new therapies, including targeted drugs, immunotherapies, and combination treatments. These advanced therapies are offering improved survival rates and better quality of life for patients, making them increasingly popular among healthcare providers. As the need for effective leukemia treatments grows, the market for leukemia therapeutics is expected to expand significantly.

How Are Technological Innovations Transforming Leukemia Treatment?

Technological innovations are transforming the landscape of leukemia treatment, leading to the development of more targeted and effective therapies. Advances in genomics and molecular biology have enabled the identification of specific genetic mutations associated with different types of leukemia, paving the way for personalized medicine. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), are designed to specifically attack cancer cells with minimal impact on healthy cells, reducing side effects and improving patient outcomes. Additionally, the rise of CAR-T cell therapy, a type of immunotherapy that uses genetically modified T cells to target leukemia cells, is revolutionizing treatment options for patients with certain types of leukemia. These technological advancements are not only enhancing the effectiveness of leukemia therapies but are also driving growth in the market.

What Are the Emerging Trends in Leukemia Therapeutics?

Several emerging trends are shaping the leukemia therapeutics market, including the increasing use of combination therapies, the development of biosimilars, and the growing focus on immunotherapy. Combination therapies, which involve using multiple drugs or treatment modalities, are showing promise in overcoming drug resistance and improving treatment outcomes. The development of biosimilars, which are lower-cost alternatives to biologic drugs, is expected to increase access to treatment, particularly in emerging markets. Immunotherapy, particularly CAR-T cell therapy, is gaining traction as a highly effective treatment option for certain types of leukemia, offering new hope for patients who have not responded to traditional therapies. These trends are contributing to the dynamic growth of the leukemia therapeutics market, as new treatment options continue to emerge.

What Factors Are Driving the Growth of the Leukemia Therapeutics Market?

The growth in the leukemia therapeutics market is driven by several factors, including the increasing prevalence of leukemia, advancements in treatment options, and the rising demand for personalized medicine. The development of targeted therapies and immunotherapies is providing new hope for patients and driving market expansion. Additionally, the growing number of clinical trials and research activities focused on leukemia is accelerating the development of new treatments. The availability of funding and investment in oncology research is also fueling market growth. As the understanding of leukemia continues to improve and new therapies are developed, the leukemia therapeutics market is expected to experience sustained growth, driven by the need for more effective and accessible treatments.

Report Scope

The report analyzes the Leukemia Therapeutics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Therapy (Chemotherapy, Immunotherapy, Other Therapies); Leukemia (Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Other Leukemias); Modality (Small-Molecule Drugs Modality, Monoclonal Antibodies Modality, CAR-T Cell Therapy Modality, Gene Therapy Modality, Bispecific Antibodies Modality, RNA-based Therapy Modality, Other Modalities); Administration Route (Oral Administration Route, Intravenous Administration Route, Subcutaneous Administration Route); Age Group (Pediatric Age Group, Adult Age Group, Geriatric Age Group).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Chemotherapy segment, which is expected to reach US$13.1 Billion by 2032 with a CAGR of a 6.1%. The Immunotherapy segment is also set to grow at 4.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $5.8 Billion in 2025, and China, forecasted to grow at an impressive 9.1% CAGR to reach $6.6 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Leukemia Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Leukemia Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Leukemia Therapeutics Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie, Inc., Amgen, Inc., Arno Therapeutics, Inc., AstraZeneca PLC, Baxter International, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Leukemia Therapeutics market report include:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Arno Therapeutics, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK Plc
  • Jazz Pharmaceuticals PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Leukemia Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for 44 Players Worldwide in 2026 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Leukemia Spurs Growth in the Leukemia Therapeutics Market
  • Advancements in Targeted Therapy Propel Adoption of Novel Leukemia Treatments
  • Growing Application of Combination Therapies Strengthens Market Demand in Leukemia Treatment
  • Shift Towards Personalized Medicine Expands Addressable Market for Leukemia Therapeutics
  • Rising Focus on Immunotherapy and CAR-T Cell Therapy Drives Innovation in Leukemia Treatment
  • Technological Innovations in Biomarker Discovery Enhance Development of Targeted Therapies
  • Expanding Use of Leukemia Therapeutics in Pediatric Oncology Generates New Opportunities
  • Rising Importance of Precision Medicine and Genomics in Leukemia Research Strengthens Demand
  • Technological Advancements in Monoclonal Antibodies and Small Molecule Inhibitors Expand Market Potential
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Leukemia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Leukemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Acute Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Acute Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Other Leukemias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Other Leukemias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Other Leukemias by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Small-Molecule Drugs Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Small-Molecule Drugs Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Small-Molecule Drugs Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Monoclonal Antibodies Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Monoclonal Antibodies Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Monoclonal Antibodies Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for CAR-T Cell Therapy Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for CAR-T Cell Therapy Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for CAR-T Cell Therapy Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Gene Therapy Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Gene Therapy Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Gene Therapy Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Bispecific Antibodies Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Bispecific Antibodies Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Bispecific Antibodies Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 38: World Recent Past, Current & Future Analysis for RNA-based Therapy Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 39: World Historic Review for RNA-based Therapy Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 40: World 13-Year Perspective for RNA-based Therapy Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 41: World Recent Past, Current & Future Analysis for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 42: World Historic Review for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 43: World 13-Year Perspective for Other Modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 44: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 45: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 46: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 47: World Recent Past, Current & Future Analysis for Intravenous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 48: World Historic Review for Intravenous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 49: World 13-Year Perspective for Intravenous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 50: World Recent Past, Current & Future Analysis for Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 51: World Historic Review for Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 52: World 13-Year Perspective for Subcutaneous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 53: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 54: World Historic Review for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 55: World 13-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 56: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 57: World Historic Review for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 58: World 13-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 59: World Recent Past, Current & Future Analysis for Geriatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 60: World Historic Review for Geriatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 61: World 13-Year Perspective for Geriatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Active Players in United States
CANADA
  • Active Players in Canada
JAPAN
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Active Players in Japan
CHINA
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Active Players in China
EUROPE
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Active Players in France
GERMANY
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Active Players in Germany
ITALY
  • Active Players in Italy
UNITED KINGDOM
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Active Players in United Kingdom
SPAIN
  • Active Players in Spain
RUSSIA
  • Active Players in Russia
REST OF EUROPE
  • Active Players in Rest of Europe
ASIA-PACIFIC
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
AUSTRALIA
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
  • Active Players in Australia
INDIA
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
  • Active Players in India
SOUTH KOREA
  • Active Players in South Korea
REST OF ASIA-PACIFIC
  • Active Players in Rest of Asia-Pacific
LATIN AMERICA
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINA
  • Active Players in Argentina
BRAZIL
  • Active Players in Brazil
MEXICO
  • Active Players in Mexico
REST OF LATIN AMERICA
  • Active Players in Rest of Latin America
MIDDLE EAST
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRAN
  • Active Players in Iran
ISRAEL
  • Active Players in Israel
SAUDI ARABIA
  • Active Players in Saudi Arabia
UNITED ARAB EMIRATES
  • Active Players in United Arab Emirates
REST OF MIDDLE EAST
  • Active Players in Rest of Middle East
AFRICA
  • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
  • Active Players in Africa
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Arno Therapeutics, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK Plc
  • Jazz Pharmaceuticals PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

Table Information